131I therapy mediated by sodium/iodide symporter combined with kringle 5 has a synergistic therapeutic effect on glioma

Shi, Shuo; Zhang, Min; Guo, Rui; Zhang, Miao; Hu, Jiajia; Xi, Yun; Miao, Ying; Li, Biao

doi:10.3892/or.2015.4420

Cited by 9 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following transfection, iodide uptake of BMSC-K5-NIS, BMSC-K5-GFP, BMSC-GFP-NIS, and BMSC cells was determined under steady-state conditions, as described previously. 16 The day before the experiment, BMSC-K5-NIS, BMSC-K5-GFP, BMSC-GFP-NIS, and BMSC cells were plated (2 • 10 5 cells/well) onto 24-well plates. After 24 h, 500 lL of Hanks' balanced salt solution (HBSS) containing 3.7 kBq of 125 I and 10 lmol/L of sodium iodide (NaI) was added.…”

Section: Uptake Assaymentioning

confidence: 99%

“…13 The authors and other researchers have successfully introduced ectopic expression of NIS by virus for imaging and therapy in nonthyroidal carcinoma. [14][15][16][17][18] To reduce immunogenicity and increase tumor tropism, virus intratumoral injection or stable therapeutic gene expression tumor cell lines were used in these studies, both of which, however, limit the clinical application, especially for patients with a disseminated malignant tumor or with tumors in deep tissues. Some studies 19,20 have reported that the early growth response factor 1 (Egr1), a radiation-sensitive promoter that can be activated by radiation, can initiate expression of downstream target genes efficiently and specifically.…”

Section: Introductionmentioning

confidence: 99%

“…22 Previous work has shown that kringle 5 (K5) of human plasminogen or K5 combined with 131 I absorbed by NIS can inhibit tumor angiogenesis. 15,16,23,24 However, these gene therapies were mediated by virus. In this study, an efficient BMSC-based therapeutic strategy was developed that simultaneously allows killing of tumor cells, inhibiting of tumor angiogenesis, and assessment and eradication of BMSCs after treatment of glioblastoma.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bone Marrow–Derived Mesenchymal Stem Cell–Mediated Dual-Gene Therapy for Glioblastoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

Bone-marrow mesenchymal stem cells (BMSCs) have been used for systemic delivery of therapeutic genes to solid tumors. However, the optimal treatment time post-BMSC implantation and the assessment of the long-term fate of therapeutic BMSCs post-tumor treatment are critical if such promising therapies are to be translated into clinical practice. An efficient BMSC-based therapeutic strategy has been developed that simultaneously allows killing of tumor cells, inhibiting of tumor angiogenesis, and assessment and eradication of implanted BMSCs after treatment of glioblastoma. BMSCs were engineered to co-express the angiogenesis inhibitor kringle 5 (K5) of human plasminogen, under the control of the cytomegalovirus promoter (CMV) and the human sodium-iodide symporter (NIS), involved in uptake of radioisotopes, under the control of early growth response factor 1 (Egr1), a radiation-activated promoter. A significant decrease in tumor growth and tumor angiogenesis and a subsequent increase in survival were observed when mice bearing glioblastoma were treated with Re post-therapeutic intravenous BMSC implantation. Furthermore, the systemic administration ofRe post-tumor treatment selectively eliminated therapeutic BMSCs expressing NIS, which was monitored in real time by I micro single photon emission computed tomography/computed tomography imaging. Meanwhile, the Egr1 promoter induced aRe radiation positive feedback effect absorbed by NIS. After intravenous BMSC implantation, BMSCs levels in the tumor and lung both peaked on day 10 and decreased to the lowest levels on days 24 and 17, respectively. These findings suggest that day 17 post-BMSC implantation could be an optimal time for Re treatment. These results provide a new adjuvant therapy mediated by BMSCs for glioblastoma treatment.

show abstract

Section: Uptake Assaymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bone Marrow–Derived Mesenchymal Stem Cell–Mediated Dual-Gene Therapy for Glioblastoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Using the early growth response factor 1 (Egr1) promoter as another radiation-activated promoter to drive NIS expression in bone marrow-derived MSCs also resulted in a 188 Re and 131 I radiation positive feedback effect in s.c. and orthotopic human glioma xenografts (U87) in mice (Shi et al 2016(Shi et al , 2019. In the orthotopic model, MSCs were engineered to co-express the angiogenesis inhibitor kringle 5 of human plasminogen and NIS, which enhanced the therapeutic efficacy of 188 Re therapy (Shi et al 2019).…”

Section: :10mentioning

confidence: 99%

The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment

Spitzweg

Nelson

Wagner³

et al. 2021

Endocrine-Related Cancer

View full text Add to dashboard Cite

Cloning of the sodium iodide symporter (NIS) 25 years ago has opened an exciting chapter in molecular thyroidology with the characterization of NIS as one of the most powerful theranostic genes and the development of a promising gene therapy strategy based on image-guided selective NIS gene transfer in non-thyroidal tumors followed by application of 131I or alternative radionuclides, such as 188Re and 211At. Over the past 2 decades significant progress has been made in the development of the NIS gene therapy concept, from local NIS gene delivery, towards promising new applications in disseminated disease, in particular, through the use of oncolytic viruses, non-viral polyplexes, and genetically engineered MSCs as highly effective, highly selective and flexible gene delivery vehicles. In addition to allowing the robust therapeutic application of radioiodine in non-thyroid cancer settings, these studies have also been able to take advantage of NIS as a sensitive reporter gene that allows temporal and spatial monitoring of vector biodistribution, replication, and elimination - critically important issues for preclinical development and clinical translation.

show abstract

“…The GBM cell line U87 was transduced with the developed LV and employed to induce tumor formation in nude mice. In this model, K5 and irradiation showed an addictive effect on glioma growth, cell proliferation and capillary density [61]. Oxidative stress may interact with cell survival: when Nox4 NADPH oxidase, which contributes to generate reactive oxygen species in GBM cells, was knocked-down via LV, tumor proliferation, invasion and radioresistance were diminished [62].…”

Section: LV As Tools For Gene and Cell Therapy Of Gbmmentioning

confidence: 99%

Lentiviral Vectors as Tools for the Study and Treatment of Glioblastoma

Vecchio

Calistri

Parolin

et al. 2019

Cancers

View full text Add to dashboard Cite

Glioblastoma (GBM) has the worst prognosis among brain tumors, hence basic biology, preclinical, and clinical studies are necessary to design effective strategies to defeat this disease. Gene transfer vectors derived from the most-studied lentivirus—the Human Immunodeficiency Virus type 1—have wide application in dissecting GBM specific features to identify potential therapeutic targets. Last-generation lentiviruses (LV), highly improved in safety profile and gene transfer capacity, are also largely employed as delivery systems of therapeutic molecules to be employed in gene therapy (GT) approaches. LV were initially used in GT protocols aimed at the expression of suicide factors to induce GBM cell death. Subsequently, LV were adopted to either express small noncoding RNAs to affect different aspects of GBM biology or to overcome the resistance to both chemo- and radiotherapy that easily develop in this tumor after initial therapy. Newer frontiers include adoption of LV for engineering T cells to express chimeric antigen receptors recognizing specific GBM antigens, or for transducing specific cell types that, due to their biological properties, can function as carriers of therapeutic molecules to the cancer mass. Finally, LV allow the setting up of improved animal models crucial for the validation of GBM specific therapies.

show abstract

131I therapy mediated by sodium/iodide symporter combined with kringle 5 has a synergistic therapeutic effect on glioma

Cited by 9 publications

References 26 publications

Bone Marrow–Derived Mesenchymal Stem Cell–Mediated Dual-Gene Therapy for Glioblastoma

Bone Marrow–Derived Mesenchymal Stem Cell–Mediated Dual-Gene Therapy for Glioblastoma

The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment

Lentiviral Vectors as Tools for the Study and Treatment of Glioblastoma

Contact Info

Product

Resources

About